摘要
目的探讨肿瘤体外药敏实验ATP生物荧光法(ATP-TCA)在肺癌化疗中的应用。方法应用ATP-TCA对48例肺癌根治术标本、6例淋巴结活检标本、4例胸腔积液标本进行药敏检测。结果ATP-TCA方法的可评估率为95%。健择(GEM)、诺维本(NVB)、阿霉素(ADM)分别与顺铂(DDP)组成两药联合方案(GP、NP、AP),它们的敏感率分别为78%、64%、27%。化疗药物对肺癌的杀伤作用具有较强的个体差异性。结论ATP-TCA是一种灵敏、可靠的肿瘤药敏感检测技术,可用于肺癌化疗中化疗药物的筛选。
Objective To study the application value of ATP based bioluminescence tumor chemoesensitivity assay （ATP-TCA） in the chemotherapy of lung cancer. Methods 48 specimens of lung cancer from resection surgery, 6 samples of lymph node biopsy and 4 samples of pleural effusion were detected by ATP-TCA. Results The evaluability was 95%. Three DDP - containing combined chemotherapy regimens：GEN and DDP regimen（GP）, NVB and DDP regimen（NP）, ADM and DDP regimen （AP）, the sensitive rates of GP, NP. AP were 78%, 64% and 27% respectively. The results suggested that different lung cancer patients responded to chemotherapeutic drugs with individualized profiles. Conclsions With the sensitivity and relia- bility, ATP-TCA is a filter method for the screening of chemotherapeutic drugs against lung cancer.
出处
《江西医学检验》
2006年第6期501-502,516,共3页
Jiangxi Journal of Medical Laboratory Sciences
关键词
生物荧光
药敏试验
肺癌
Bioluminescence
Chemoesensitivity assay
Lung cancer
